PMID- 36799543
OWN - NLM
STAT- MEDLINE
DCOM- 20230515
LR  - 20230515
IS  - 2724-5772 (Electronic)
IS  - 2724-5683 (Linking)
VI  - 71
IP  - 3
DP  - 2023 Jun
TI  - Safety and feasibility of angiotensin receptor neprilysin inhibitor in real-world 
      patients with acute decompensated heart failure.
PG  - 266-274
LID - 10.23736/S2724-5683.22.06182-8 [doi]
AB  - BACKGROUND: The aim of this study was to determine the safety and feasibility of 
      in-hospital sacubitril/valsartan initiation after clinical stabilization in 
      patients with acute decompensated heart failure (ADHF) and reduced ejection 
      fraction (EF). METHODS: This retrospective, multicenter observational study 
      included patients admitted for ADHF in 2 Italian centers between February 2017 
      and January 2022. Feasibility was evaluated by assessing the proportion of 
      patients discharged on sacubitril/valsartan. Key safety endpoints were the 
      incidences of adverse events during hospitalization and during follow-up planned 
      at 1 month, 3-6 months and 12-18 months after discharge. RESULTS: One hundred and 
      twenty-two patients were included. Median age was 71 (60-78) years, 78% male, 63% 
      New York Heart Association (NYHA) Class III at admission with a median left 
      ventricular ejection fraction (EF) of 25% (20-30). During hospitalization, 94 
      (77%) patients were treated with intravenous diuretics, 39 (32%) with 
      inotrope/vasopressor, 51 (42%) with continuous positive airway pressure 
      ventilation and 7 (6%) were assisted with an intra-aortic balloon pump. Median 
      time from hospitalization to sacubitril/valsartan initiation was 4 (2-7) days. 
      Sacubitril/valsartan was started at a dosage of 12/13 mg in 52 (43%) patients, 
      24/26 mg in 61 (50%) patients and 49/51 mg in 8 (7%) patients. Overall, 111 (91%) 
      patients were discharged on sacubitril/valsartan. At 12-18-month follow-up, the 
      vast majority of patients were still on sacubitril/valsartan therapy. 
      CONCLUSIONS: In-hospital initiation of sacubitril/valsartan treatment in 
      real-world ADHF patients may be a safe and feasible treatment option.
FAU - Rossini, Roberta
AU  - Rossini R
AD  - Division of Cardiology, Santa Croce e Carle Hospital, Cuneo, Italy - 
      roberta.rossini2@gmail.com.
FAU - Angelini, Filippo
AU  - Angelini F
AD  - Division of Cardiology, Cardiovascular and Thoracic Surgery Department, 
      "Citta della Salute e della Scienza" Hospital, Turin, Italy.
FAU - Giordana, Francesca
AU  - Giordana F
AD  - Division of Cardiology, Santa Croce e Carle Hospital, Cuneo, Italy.
FAU - Coppini, Lucia
AU  - Coppini L
AD  - Division of Cardiology, Santa Croce e Carle Hospital, Cuneo, Italy.
FAU - Ferraro, Ilenia
AU  - Ferraro I
AD  - Division of Cardiology, Santa Croce e Carle Hospital, Cuneo, Italy.
FAU - Ruffino, Enrico
AU  - Ruffino E
AD  - Division of Cardiology, Santa Croce e Carle Hospital, Cuneo, Italy.
FAU - Varbella, Ferdinando
AU  - Varbella F
AD  - Ospedale degli Infermi di Rivoli, Rivoli, Turin, Italy.
FAU - Tizzani, Emanuele
AU  - Tizzani E
AD  - Ospedale degli Infermi di Rivoli, Rivoli, Turin, Italy.
FAU - Valente, Eduardo
AU  - Valente E
AD  - Division of Cardiology, Cardiovascular and Thoracic Surgery Department, 
      "Citta della Salute e della Scienza" Hospital, Turin, Italy.
FAU - Musumeci, Giuseppe
AU  - Musumeci G
AD  - Division of Cardiology, AO Ordine Mauriziano, Turin, Italy.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Observational Study
DEP - 20230217
PL  - Italy
TA  - Minerva Cardiol Angiol
JT  - Minerva cardiology and angiology
JID - 101776555
RN  - 17ERJ0MKGI (sacubitril)
RN  - EC 3.4.24.11 (Neprilysin)
RN  - 0 (Tetrazoles)
RN  - 80M03YXJ7I (Valsartan)
RN  - 0 (Aminobutyrates)
RN  - 0 (Biphenyl Compounds)
RN  - 0 (Antihypertensive Agents)
SB  - IM
MH  - Humans
MH  - Male
MH  - Aged
MH  - Female
MH  - *Neprilysin/pharmacology/therapeutic use
MH  - Stroke Volume
MH  - Retrospective Studies
MH  - Feasibility Studies
MH  - Tetrazoles/adverse effects
MH  - Ventricular Function, Left
MH  - Treatment Outcome
MH  - Valsartan/therapeutic use/pharmacology
MH  - *Heart Failure/drug therapy
MH  - Aminobutyrates/adverse effects
MH  - Biphenyl Compounds/therapeutic use/pharmacology
MH  - Antihypertensive Agents/therapeutic use
EDAT- 2023/02/18 06:00
MHDA- 2023/05/15 06:42
CRDT- 2023/02/17 08:33
PHST- 2023/05/15 06:42 [medline]
PHST- 2023/02/18 06:00 [pubmed]
PHST- 2023/02/17 08:33 [entrez]
AID - S2724-5683.22.06182-8 [pii]
AID - 10.23736/S2724-5683.22.06182-8 [doi]
PST - ppublish
SO  - Minerva Cardiol Angiol. 2023 Jun;71(3):266-274. doi: 
      10.23736/S2724-5683.22.06182-8. Epub 2023 Feb 17.